Some of the recent studies11, 12, 13, 14, 17show results of experimental gene targeting pharmaceutical therapy with sirolimus, ARQ 092, or miransertib-AKT1 inhibitors, originally designed to treat cancer. Here, AKT1 is linked to cancer.